全文获取类型
收费全文 | 1727篇 |
免费 | 184篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 68篇 |
妇产科学 | 11篇 |
基础医学 | 114篇 |
口腔科学 | 35篇 |
临床医学 | 201篇 |
内科学 | 476篇 |
皮肤病学 | 24篇 |
神经病学 | 70篇 |
特种医学 | 262篇 |
外国民族医学 | 1篇 |
外科学 | 203篇 |
综合类 | 32篇 |
一般理论 | 1篇 |
预防医学 | 51篇 |
眼科学 | 37篇 |
药学 | 65篇 |
中国医学 | 5篇 |
肿瘤学 | 240篇 |
出版年
2023年 | 24篇 |
2022年 | 11篇 |
2021年 | 51篇 |
2020年 | 39篇 |
2019年 | 46篇 |
2018年 | 74篇 |
2017年 | 49篇 |
2016年 | 48篇 |
2015年 | 56篇 |
2014年 | 64篇 |
2013年 | 70篇 |
2012年 | 94篇 |
2011年 | 98篇 |
2010年 | 68篇 |
2009年 | 76篇 |
2008年 | 60篇 |
2007年 | 50篇 |
2006年 | 47篇 |
2005年 | 38篇 |
2004年 | 35篇 |
2003年 | 35篇 |
2002年 | 35篇 |
2001年 | 31篇 |
2000年 | 25篇 |
1999年 | 23篇 |
1998年 | 52篇 |
1997年 | 53篇 |
1996年 | 66篇 |
1995年 | 49篇 |
1994年 | 43篇 |
1993年 | 49篇 |
1992年 | 18篇 |
1991年 | 12篇 |
1990年 | 16篇 |
1989年 | 36篇 |
1988年 | 34篇 |
1987年 | 39篇 |
1986年 | 37篇 |
1985年 | 28篇 |
1984年 | 19篇 |
1983年 | 10篇 |
1982年 | 23篇 |
1981年 | 14篇 |
1980年 | 8篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1977年 | 13篇 |
1976年 | 11篇 |
1975年 | 13篇 |
1973年 | 4篇 |
排序方式: 共有1918条查询结果,搜索用时 15 毫秒
1.
Hagop Kantarjian Tapan Kadia Courtney DiNardo Naval Daver Gautam Borthakur Elias Jabbour Guillermo Garcia-Manero Marina Konopleva Farhad Ravandi 《Blood cancer journal》2021,11(2)
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.Subject terms: Prognosis, Health services 相似文献
2.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
3.
4.
5.
6.
7.
8.
9.
10.